Navigation Links
Callisto Pharmaceuticals Announces Publication of Research Article,on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

Article Published in Recent Issue of Journal Blood

NEW YORK, April 11, 2007 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the publication of a research article on Atiprimod, Callisto's drug currently in clinical trials in carcinoid cancer and multiple myeloma patients, in the February 2007 issue of Blood, a peer-reviewed scientific journal that publishes original research articles related to hematological malignancies.

The article authored by Dr. Michael Wang and Dr. Qing Yi, from the University of Texas M.D. Anderson Cancer Center, focuses on Atiprimod's ability to inhibit proliferation of mantle cell lymphoma (MCL) cells in vitro and to inhibit growth of MCL tumors in tumor-bearing mice. The animal data demonstrated that Atiprimod significantly inhibited tumor growth in vivo and prolonged survival of tumor-bearing mice. Atiprimod was shown to enhance release of apoptosis-inducing factor (AIF) from cellular mitochondria, and the authors suggest that this is the mechanism of Atiprimod's apoptotic (programmed cellular death) activity.

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients.

The publication appeared in Blood First Edition Paper, prepublished online February 22, 2007 DOI 10.1182/Blood-2006-12-063958 and is titled: "Atiprimod inhibits the growth of mantle cell lymph
'"/>




Page: 1 2 3

Related medicine technology :

1. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 /PRNewswire/ ... to grow, with the publication of two papers this ... Otolaryngology – Head and Neck Surgery , ... both objective and subjective measures of sleep disordered breathing, ... for the reduction in obstructive sleep apnea severity and ...
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... conferences in September: Stifel Nicolaus Healthcare Conference Thursday, ... UBS Global Life Sciences Conference Wednesday, September 21, at 9:30 ... of each event will be available on the Investor Relations ...
... Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today ... presenting at two upcoming investor conferences taking place in New ... will present at the Rodman and Renshaw Annual Global Investment ... On Wednesday, September 14, Mr. Shortall will present at the ...
Cached Medicine Technology:Unilife to Participate in Two Investor Conferences 2
(Date:9/20/2014)... 2014 "As a nurse, patients always ask ... an inventor from Tamaqua, Pa. "The reason that they cannot ... of their chairs. My invention enables them to check oxygen ... Sensor to make it easier to monitor the contents of ... when the tank is low. It allows changeovers to be ...
(Date:9/20/2014)... September 20, 2014 QueenBeeTickets.com is ready ... star’s tour performances. She will visit many cities in ... until the 16th of April. , Click Here ... Tour tickets at QueenBeeTickets.com. , The star’s fans are ... see their favorite young singer in a live performance. ...
(Date:9/20/2014)... The first federal bellwether trial of a DePuy ... in the U.S. District Court, Northern District of Texas, ... the week opened in the DePuy Pinnacle Hip ... vice president, who discussed the clinical testing performed on ... According to Reuters, the executive stated that the Pinnacle ...
(Date:9/19/2014)... 2014 Nearly 780 Risperdal lawsuits are ... where a meeting took place to discuss the next ... in the court’s mass tort program. Attorneys for the ... week at the Complex Litigation Center in Philadelphia’s City ... proceedings. The Risperdal lawsuits filed against Johnson & Johnson ...
(Date:9/19/2014)... City, KS (PRWEB) September 19, 2014 ... is responding to families in regions of the Philippines being ... , More than 1,060 families evacuated to the nearest ... storm Fung-Wong brought heavy rain and gusty winds to portions ... Friday causing heavy flooding. Some homes filled with more than ...
Breaking Medicine News(10 mins):Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2
... Maureen Salamon HealthDay Reporter , TUESDAY, Aug. ... investigating injectable drugs to treat psoriasis -- an autoimmune ... medications are not linked to higher heart risks. ... information from drug makers impeded their ability to assess ...
... bowel disease (IBD), which affects more than 1 million ... response triggered by environmental factors, such as bacteria, in ... inflammation of the lining of the colon, is one ... IBD is prompted by different cytokines small signaling ...
... Reporter , TUESDAY, Aug. 23 (HealthDay News) -- A test ... are most likely to raise the risk of invasive cervical ... accurate for many women than the Pap test alone, a ... HPV-positive, using the HPV test alone appears to be enough, ...
... are to investigate whether the therapeutic effects of clay ... of anger, anxiety and depression. Academics are teaming ... gallery and local artists for the innovative project that ... offer to young people struggling with mental health problems. ...
... psychology department show that people who use more ... are viewed more negatively than those who use milder ... adults are more negative about using anti-aging methods than ... rapid growth of the anti-aging cosmetic industry, age concealment ...
... drug and mental disorders would benefit greatly from smoking ... be five times more successful at kicking the habit, ... Center has found. Smokers with these comorbid conditions ... have a more difficult time quitting and represent a ...
Cached Medicine News:Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:Novel cytokine protects mice from colitis 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3Health News:Modelling emotions: A potential new therapy for disturbed teenagers 2Health News:Modelling emotions: A potential new therapy for disturbed teenagers 3Health News:U of T research shows anti-aging techniques not yet viewed as acceptable 2Health News:Smokers with comorbid conditions need help from their doctor to quit 2Health News:Smokers with comorbid conditions need help from their doctor to quit 3
... a sterile, nonpyrogenic, viscoelastic preparation of ... weight fraction of sodium hyaluronate., ,Healon ... dissolved in physiological sodium chloride phosphate ... weight polymer is made up of ...
... DUOVISC Viscoelastic System is designed to ... properties that can be used differently and ... cataract procedure. The choice of the viscoelastic ... differential ability of each to facilitate performance ...
... fiscal year 2004, Biomet plans to ... to the global market, enhancing visualization ... Acumen technology was developed in conjunction ... based in Hollywood, Florida. Procedure-specific software ...
... in awhile, a product comes along that ... in its category. The new StealthStation TREON ... a product. Built on the phenomenal success ... surgical navigation system in the worldthe new ...
Medicine Products: